🇺🇸 FDA
Patent

US 8420816

Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK

granted A61KA61K31/4375A61K31/4545

Quick answer

US patent 8420816 (Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK) held by Takeda Pharmaceutical Company Limited expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/4375, A61K31/4545, A61K31/496, A61K31/506